Houpert R, Veronique-Baudin J, Almont T, Beaubrun-Renard M, Boullard M, Pierre-Louis A
BMC Cancer. 2024; 24(1):1500.
PMID: 39639185
PMC: 11619627.
DOI: 10.1186/s12885-024-13221-6.
Di Francesco A, Pasciuto G, Verrecchia E, Sicignano L, Gerardino L, Massaro M
J Clin Med. 2024; 13(17).
PMID: 39274446
PMC: 11396756.
DOI: 10.3390/jcm13175232.
Viezens I, Knierim E, Deubzer H, Hauptmann K, Fassbender J, Morales-Gonzalez S
Cancers (Basel). 2024; 16(13).
PMID: 39001514
PMC: 11240514.
DOI: 10.3390/cancers16132452.
Houpert R, Almont T, Belahreche R, Faro M, Okouango J, Vestris M
BMC Cancer. 2023; 23(1):1197.
PMID: 38057723
PMC: 10702113.
DOI: 10.1186/s12885-023-11666-9.
Yu J, Refsum E, Wieszczy P, Helsingen L, Perrin V, Hogden A
BMJ Open Gastroenterol. 2023; 10(1).
PMID: 37142293
PMC: 10163486.
DOI: 10.1136/bmjgast-2022-001037.
Identification of ultra-rare genetic variants in pediatric acute onset neuropsychiatric syndrome (PANS) by exome and whole genome sequencing.
Trifiletti R, Lachman H, Manusama O, Zheng D, Spalice A, Chiurazzi P
Sci Rep. 2022; 12(1):11106.
PMID: 35773312
PMC: 9246359.
DOI: 10.1038/s41598-022-15279-3.
Somatic Mutations and Autoimmunity.
Alriyami M, Polychronakos C
Cells. 2021; 10(8).
PMID: 34440825
PMC: 8394445.
DOI: 10.3390/cells10082056.
Sarcoidosis and Cancer: A Complex Relationship.
El Jammal T, Pavic M, Gerfaud-Valentin M, Jamilloux Y, Seve P
Front Med (Lausanne). 2020; 7:594118.
PMID: 33330555
PMC: 7732692.
DOI: 10.3389/fmed.2020.594118.
Autoimmune disease is associated with a lower risk of progression in monoclonal gammopathy of undetermined significance.
Baldursdottir T, Love B, Gislason G, Bjorkholm M, Mellqvist U, Lund S
Eur J Haematol. 2020; 106(3):380-388.
PMID: 33295006
PMC: 9206721.
DOI: 10.1111/ejh.13563.
Risk of mature B-cell neoplasms and precursor conditions after joint replacement: A report from the Haematological Malignancy Research Network.
Kane E, Painter D, Smith A, Lamb M, Oliver S, Patmore R
Int J Cancer. 2019; 147(3):702-708.
PMID: 31675431
PMC: 7317514.
DOI: 10.1002/ijc.32765.
Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility.
Sud A, Thomsen H, Law P, Forsti A, da Silva Filho M, Holroyd A
Nat Commun. 2017; 8(1):1892.
PMID: 29196614
PMC: 5711884.
DOI: 10.1038/s41467-017-00320-1.
Autoimmune and Atopic Disorders and Risk of Classical Hodgkin Lymphoma.
Hollander P, Rostgaard K, Smedby K, Chang E, Amini R, de Nully Brown P
Am J Epidemiol. 2015; 182(7):624-32.
PMID: 26346543
PMC: 4581588.
DOI: 10.1093/aje/kwv081.
Hodgkin lymphoma risk following infectious and chronic inflammatory diseases: a large population-based case-control study from Sweden.
Kristinsson S, Gao Y, Bjorkholm M, Lund S, Sjoberg J, Caporaso N
Int J Hematol. 2015; 101(6):563-8.
PMID: 25758095
DOI: 10.1007/s12185-015-1772-6.
Adjuvants and lymphoma risk as part of the ASIA spectrum.
Butnaru D, Shoenfeld Y
Immunol Res. 2015; 61(1-2):79-89.
PMID: 25582758
DOI: 10.1007/s12026-014-8622-0.
Infectious, autoimmune and allergic diseases and risk of Hodgkin lymphoma in children and adolescents: a Children's Oncology Group study.
Linabery A, Erhardt E, Fonstad R, Ambinder R, Bunin G, Ross J
Int J Cancer. 2014; 135(6):1454-69.
PMID: 24523151
PMC: 4107091.
DOI: 10.1002/ijc.28785.
Modifiers and subtype-specific analyses in whole-genome association studies: a likelihood framework.
Lee P, Bergen S, Perlis R, Sullivan P, Sklar P, Smoller J
Hum Hered. 2011; 72(1):10-20.
PMID: 21849790
PMC: 7077092.
DOI: 10.1159/000327158.
Autoimmunity and the risk of myeloproliferative neoplasms.
Kristinsson S, Landgren O, Samuelsson J, Bjorkholm M, Goldin L
Haematologica. 2010; 95(7):1216-20.
PMID: 20053870
PMC: 2895049.
DOI: 10.3324/haematol.2009.020412.
